cyclic-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine profile

cyclic-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine: prodrug for HPMPC; specific name and structure not given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	122873
CHEMBL ID	392630
SCHEMBL ID	140858
MeSH ID	M0196555

Synonym
1-((2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl)cytosine
2(1h)-pyrimidinone, 4-amino-1-((2-hydroxy-1,4,2-dioxaphosphorinan-5-yl)methyl)-, p-oxide, (s)-
gs 930
(s)-4-amino-1-((2-hydroxy-1,4,2-dioxaphosphorinan-5-yl)methyl)-2(1h)-pyrimidinone p-oxide
cyclic-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine
cyclic-hpmpc
4-amino-1-[[(5s)-2-hydroxy-2-oxo-1,4,2$l^{5}-dioxaphosphinan-5-yl]methyl]pyrimidin-2-one
ccdv
chpmpc
1-[((5)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine
127757-45-3
cyclic hpmpc, gs 0930
cyclic(s)-hpmpc
cyclic cidofovir
CHEMBL392630
YXQUGSXUDFTPLL-LURJTMIESA-N
cyclic hpmpc
bo8prp86rh ,
1-(((s)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl)cytosine (cyclic hpmpc)
unii-bo8prp86rh
SCHEMBL140858
DTXSID00155660
bdbm50485549
2(1h)-pyrimidinone, 4-amino-1-(((5s)-2-hydroxy-2-oxido-1,4,2-dioxaphosphorinan-5-yl)methyl)-
1-(((s)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl)cytosine
1-[((s)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine
4-amino-1-[[(5s)-2-hydroxy-2-oxo-1,4,2lambda5-dioxaphosphinan-5-yl]methyl]pyrimidin-2-one
HY-147014

Excerpt	Reference	Relevance
" Further, blood chemistry analysis showed no adverse effects of CHPMPC treatment on kidney or liver function."	( Cyclic HPMPC is safe and effective against systemic guinea pig cytomegalovirus infection in immune compromised animals. Bernstein, DI; Bourne, N; Bravo, FJ, 2000)	0.31

Excerpt	Reference	Relevance
" These mt-QSARs offer also a good opportunity to construct drug-drug Complex Networks (CNs) that can be used to explore large and complex drug-viral species databases."	( Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E, 2009)	0.35

Excerpt	Reference	Relevance
" The subcutaneous bioavailability of cidofovir was 91."	( Pharmacokinetics, bioavailability, metabolism, and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats. Bidgood, AM; Cundy, KC; Griffin, L; Lee, WA; Lynch, G; Shaw, JP, 1996)	0.29
"The pharmacokinetics and bioavailability of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosi ne (cyclic HPMPC) were examined at four doses in 22 patients with human immunodeficiency virus infection."	( Clinical pharmacokinetics of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine in human immunodeficiency virus-infected patients. Barditch-Crovo, P; Cundy, KC; Jaffe, HS; Lietman, PS; Petty, BG; Redpath, M; Ruby, A, 1999)	0.3
" Two prodrugs (3 and 4) created by conjugating ethylene glycol-linked amino acids (L-Val, L-Phe) with the cyclic form of cidofovir (cHPMPC) via a P-O ester bond were synthesized and their pH-dependent stability (3 and 4), potential for in vivo reconversion to drug (3), and oral bioavailability (3) were evaluated."	( Synthesis and biological activation of an ethylene glycol-linked amino acid conjugate of cyclic cidofovir. Borysko, KZ; Breitenbach, JM; Drach, JC; Eriksson, U; Hilfinger, JM; Kashemirov, BA; Kijek, P; Kim, JS; McKenna, CE; Mitchell, S, 2007)	0.34
" The results indicate that the previously observed enhanced oral bioavailability of 2a relative to the parent drug is unlikely to be due to active transport by hPEPT1."	( Serine side chain-linked peptidomimetic conjugates of cyclic HPMPC and HPMPA: synthesis and interaction with hPEPT1. Kashemirov, BA; Krylov, IS; McKenna, CE; Peterson, LW; Sala-Rabanal, M; Serpi, M, 2010)	0.36
" (l)-Tyr-NH-i-Bu cHPMPA (11) was converted in rat or mouse plasma solely to two active metabolites and had significantly enhanced oral bioavailability vs parent drug 1 in a mouse model (39% vs <5%)."	( Tyrosine-based 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine and -adenine ((S)-HPMPC and (S)-HPMPA) prodrugs: synthesis, stability, antiviral activity, and in vivo transport studies. Borysko, KZ; Breitenbach, JM; Collins, M; Drach, JC; Hilfinger, JM; Kashemirov, BA; Krylov, IS; McKenna, CE; Peterson, LW; Serpi, M; Zakharova, VM, 2011)	0.37

Excerpt	Relevance	Reference
" Radioactivity in vitreous at 240 h after intravitreal dosing with either drug contained cidofovir, cyclic HPMPC and cidofovir-phosphocholine."	( Distribution and metabolism of intravitreal cidofovir and cyclic HPMPC in rabbits. Cundy, KC; Hitchcock, MJ; Lee, WA; Lynch, G; Shaw, JP, 1996)	0.29
" Transport studies in a rat model have shown enhanced levels of total cidofovir species in the plasma after oral dosing with L-Val-L-Ser-OMe cHPMPC, 2a."	( Serine side chain-linked peptidomimetic conjugates of cyclic HPMPC and HPMPA: synthesis and interaction with hPEPT1. Kashemirov, BA; Krylov, IS; McKenna, CE; Peterson, LW; Sala-Rabanal, M; Serpi, M, 2010)	0.36

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Solute carrier family 22 member 6	Homo sapiens (human)	IC50 (µMol)	1,100.0000	0.2700	4.5306	9.9000	AID681331
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Solute carrier family 22 member 6	Homo sapiens (human)	Km	309.0000	0.4200	4.6183	9.3000	AID679322
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
monoatomic anion transport	Solute carrier family 22 member 6	Homo sapiens (human)
response to organic cyclic compound	Solute carrier family 22 member 6	Homo sapiens (human)
inorganic anion transport	Solute carrier family 22 member 6	Homo sapiens (human)
organic anion transport	Solute carrier family 22 member 6	Homo sapiens (human)
prostaglandin transport	Solute carrier family 22 member 6	Homo sapiens (human)
alpha-ketoglutarate transport	Solute carrier family 22 member 6	Homo sapiens (human)
xenobiotic transport	Solute carrier family 22 member 6	Homo sapiens (human)
sodium-independent organic anion transport	Solute carrier family 22 member 6	Homo sapiens (human)
transmembrane transport	Solute carrier family 22 member 6	Homo sapiens (human)
metanephric proximal tubule development	Solute carrier family 22 member 6	Homo sapiens (human)
renal tubular secretion	Solute carrier family 22 member 6	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
solute:inorganic anion antiporter activity	Solute carrier family 22 member 6	Homo sapiens (human)
protein binding	Solute carrier family 22 member 6	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier family 22 member 6	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Solute carrier family 22 member 6	Homo sapiens (human)
alpha-ketoglutarate transmembrane transporter activity	Solute carrier family 22 member 6	Homo sapiens (human)
antiporter activity	Solute carrier family 22 member 6	Homo sapiens (human)
transmembrane transporter activity	Solute carrier family 22 member 6	Homo sapiens (human)
chloride ion binding	Solute carrier family 22 member 6	Homo sapiens (human)
identical protein binding	Solute carrier family 22 member 6	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Solute carrier family 22 member 6	Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activity	Solute carrier family 22 member 6	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Solute carrier family 22 member 6	Homo sapiens (human)
caveola	Solute carrier family 22 member 6	Homo sapiens (human)
basal plasma membrane	Solute carrier family 22 member 6	Homo sapiens (human)
basolateral plasma membrane	Solute carrier family 22 member 6	Homo sapiens (human)
extracellular exosome	Solute carrier family 22 member 6	Homo sapiens (human)
protein-containing complex	Solute carrier family 22 member 6	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (91)

Assay ID	Title	Year	Journal	Article
AID392536	Antiviral activity against Vaccinia virus	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID324765	Antiviral activity against Simian virus 40 PML1 EK in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains.
AID324760	Selectivity index, ratio of CC50 for mouse UC1B cells to EC50 of Murine polyomavirus MN/RDE Toronto	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains.
AID303230	Antiviral activity against Coxsackie virus B4 in HeLa cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID303211	Antiviral activity against HSV2 Lyons in HEL cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID303234	Antiviral activity against Reovirus 1 in Vero cells reduction of virus-induced cytopathogenicity after 4 days	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID606842	Antiviral activity against Human cytomegalovirus Towne infected in HFF cells assessed as reduction in plaque formation after 10 days	2011	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13	Synthesis, transport and antiviral activity of Ala-Ser and Val-Ser prodrugs of cidofovir.
AID374223	Antiviral activity against Camelpox virus CML1 infected in differentiated human PHK raft culture assessed as reduction in viral titer determined in HEL299 cells treated after 7 days postinfection by virus yield reduction assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID374207	Antiviral activity against Camelpox virus CML1 infected in human PHK assessed as reduction in viral titer after 6 days postinfection by virus yield reduction assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID606840	Antiviral activity against Vaccinia virus Copenhagen infected in HFF cells assessed as reduction in plaque formation after 3 days	2011	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13	Synthesis, transport and antiviral activity of Ala-Ser and Val-Ser prodrugs of cidofovir.
AID636699	Cytotoxicity against human KB cells after 48 hrs by crystal violet staining based spectrophotometric analysis	2011	Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16	Tyrosine-based 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine and -adenine ((S)-HPMPC and (S)-HPMPA) prodrugs: synthesis, stability, antiviral activity, and in vivo transport studies.
AID303220	Antiviral activity against vaccinia virus Lederle in HEL cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID374205	Antiviral activity against Camelpox virus CML1 infected in HEL299 cells assessed as reduction in viral titer after 6 days postinfection by virus yield reduction assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID303231	Antiviral activity against Coxsackie virus B4 in Vero cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID374194	Antiviral activity against Camelpox virus CML14 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID303229	Antiviral activity against VSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID374204	Cytotoxicity against human PHK assessed as minimum cytotoxic concentration required for alteration in cell morphology after 4 days by microscopy	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID293242	AUC (0 to infinity) in rat at 3 mg, po	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Synthesis and biological activation of an ethylene glycol-linked amino acid conjugate of cyclic cidofovir.
AID324767	Cytotoxicity against african green monkey BSC1 cells	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains.
AID636697	Antiviral activity against HSV1 KOS infected in HFF cells incubated for 3 days by plaque reduction assay	2011	Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16	Tyrosine-based 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine and -adenine ((S)-HPMPC and (S)-HPMPA) prodrugs: synthesis, stability, antiviral activity, and in vivo transport studies.
AID293243	Bioavailability in rat at 3 mg, iv	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Synthesis and biological activation of an ethylene glycol-linked amino acid conjugate of cyclic cidofovir.
AID303221	Cytotoxicity against HEL cells assessed as alteration in morphology after 3 days	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID303213	Antiviral activity against VZV OKA in HEL cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID293228	Stability in phosphate buffer in pH 3 at 37 degC at 500 uM	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Synthesis and biological activation of an ethylene glycol-linked amino acid conjugate of cyclic cidofovir.
AID679322	TP_TRANSPORTER: uptake in OAT1-expressing CHO cells	2000	Analytical biochemistry, Jul-15, Volume: 283, Issue:1	Fluorescence-based assay for the interaction of small molecules with the human renal organic anion transporter 1.
AID293238	Half life in Sprague-Dawley rat intestinal lumen in 37degC at 500 uM	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Synthesis and biological activation of an ethylene glycol-linked amino acid conjugate of cyclic cidofovir.
AID293231	Stability in phosphate buffer in pH 6 at 37 degC at 500 uM	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Synthesis and biological activation of an ethylene glycol-linked amino acid conjugate of cyclic cidofovir.
AID293233	Stability in phosphate buffer in pH 7 at 37 degC at 500 uM	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Synthesis and biological activation of an ethylene glycol-linked amino acid conjugate of cyclic cidofovir.
AID374199	Antiviral activity against Camelpox virus CML14 infected in human PHK assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID374203	Cytotoxicity against HEL299 cells assessed as minimum cytotoxic concentration required for alteration in cell morphology after 4 days by microscopy	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID303210	Antiviral activity against acyclovir-resistant HSV1 KOS TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID303235	Antiviral activity against Sindbis virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID293235	Half life in rat intestine in 37degC at 500 uM	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Synthesis and biological activation of an ethylene glycol-linked amino acid conjugate of cyclic cidofovir.
AID324766	Antiviral activity against Simian virus 40 PML2 DAR in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains.
AID324755	Antiviral activity against Murine polyomavirus MN/RDE Toronto in mouse UC1B cells assessed as reduction of virus-induced cytopathogenicity	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains.
AID303239	Cytotoxicity against C3H cells assessed as alteration in morphology after 3 days	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID636700	Cytotoxicity against HFF cells after 48 hrs by visual cytotoxicity observation assay	2011	Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16	Tyrosine-based 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine and -adenine ((S)-HPMPC and (S)-HPMPA) prodrugs: synthesis, stability, antiviral activity, and in vivo transport studies.
AID636696	Antiviral activity against Vaccinia virus Copenhagen infected in HFF cells incubated for 3 days by plaque reduction assay	2011	Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16	Tyrosine-based 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine and -adenine ((S)-HPMPC and (S)-HPMPA) prodrugs: synthesis, stability, antiviral activity, and in vivo transport studies.
AID303224	Cytotoxicity against HEL cells assessed as cell growth after 3 days	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID324770	Selectivity index, ratio of CC50 for african green monkey BSC1 cells ot EC50 for Simian virus 40 PML2 DAR	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains.
AID392533	Antiviral activity against Monkeypox virus	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID324759	Cytotoxicity against mouse UC1B cells	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains.
AID303226	Antiviral activity against HIV2 ROD in CEM cells assessed as reduction of virus-induced cytopathogenicity after 4 days	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID636695	Antiviral activity against Cowpox virus Brighton infected in HFF cells incubated for 3 days by plaque reduction assay	2011	Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16	Tyrosine-based 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine and -adenine ((S)-HPMPC and (S)-HPMPA) prodrugs: synthesis, stability, antiviral activity, and in vivo transport studies.
AID303236	Antiviral activity against Punta Toro virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID324757	Antiviral activity against Murine polyomavirus 2PTA2 in mouse UC1B cells assessed as reduction of virus-induced cytopathogenicity	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains.
AID392504	Antiviral activity against Cowpox virus	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID303214	Antiviral activity against VZV 07-1 TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID303212	Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID324758	Antiviral activity against Murine polyomavirus LID1 ATCC VR-252 in mouse UC1B cells assessed as reduction of virus-induced cytopathogenicity	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains.
AID636698	Antiviral activity against HCMV Towne infected in HFF cells incubated for 10 days by plaque reduction assay	2011	Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16	Tyrosine-based 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine and -adenine ((S)-HPMPC and (S)-HPMPA) prodrugs: synthesis, stability, antiviral activity, and in vivo transport studies.
AID324763	Selectivity index, ratio of CC50 for mouse UC1B cells to EC50 of Murine polyomavirus LID1	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains.
AID303228	Antiviral activity against VSV in HEL cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID303232	Antiviral activity against RSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID374202	Selectivity index, ratio of CC50 for human PHK to EC50 for Camelpox virus CML14 infected in human PHK	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID293229	Stability in phosphate buffer in pH 4 at 37 degC at 500 uM	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Synthesis and biological activation of an ethylene glycol-linked amino acid conjugate of cyclic cidofovir.
AID293230	Stability in phosphate buffer in pH 5 at 37 degC at 500 uM	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Synthesis and biological activation of an ethylene glycol-linked amino acid conjugate of cyclic cidofovir.
AID324761	Selectivity index, ratio of CC50 for mouse UC1B cells to EC50 of Murine polyomavirus PTA	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains.
AID374198	Antiviral activity against Camelpox virus CML1 infected in human PHK assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID374200	Cytotoxicity against human PHK after 4 days by Z1 Coulter counting analysis	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID324762	Selectivity index, ratio of CC50 for mouse UC1B cells to EC50 of Murine polyomavirus 2PTA2	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains.
AID374197	Selectivity index, ratio of CC50 for HEL299 cells to EC50 for Camelpox virus CML14 infected in HEL299 cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID293237	Half life in HFF cells in 37degC at 500 uM	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Synthesis and biological activation of an ethylene glycol-linked amino acid conjugate of cyclic cidofovir.
AID606773	Cytotoxicity against human KB cells after 48 hrs by crystal violet staining technique	2011	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13	Synthesis, transport and antiviral activity of Ala-Ser and Val-Ser prodrugs of cidofovir.
AID606841	Antiviral activity against Cowpox virus Brighton infected in HFF cells assessed as reduction in plaque formation after 3 days	2011	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13	Synthesis, transport and antiviral activity of Ala-Ser and Val-Ser prodrugs of cidofovir.
AID374196	Selectivity index, ratio of CC50 for HEL299 cells to EC50 for Camelpox virus CML1 infected in HEL299 cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID374195	Cytotoxicity against HEL299 cells after 4 days by Z1 Coulter counting analysis	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID606772	Cytotoxicity against HFF cells	2011	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13	Synthesis, transport and antiviral activity of Ala-Ser and Val-Ser prodrugs of cidofovir.
AID303233	Antiviral activity against Parainfluenza 3 in Vero cells reduction of virus-induced cytopathogenicity after 4 days	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID374201	Selectivity index, ratio of CC50 for human PHK to EC50 for Camelpox virus CML1 infected in human PHK	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID303215	Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID303227	Antiviral activity against MSV in C3H cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID293241	AUC (0 to infinity) in rat at 0.1 mg, iv	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Synthesis and biological activation of an ethylene glycol-linked amino acid conjugate of cyclic cidofovir.
AID324769	Selectivity index, ratio of CC50 for african green monkey BSC1 cells ot EC50 for Simian virus 40 PML1 EK	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains.
AID324764	Antiviral activity against Simian virus 40 A2895 in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains.
AID303225	Antiviral activity against HIV1 3B in CEM cells assessed as reduction of virus-induced cytopathogenicity after 4 days	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID303216	Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID303238	Cytotoxicity against Vero cells assessed as alteration in morphology after 3 days	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID324768	Selectivity index, ratio of CC50 for african green monkey BSC1 cells ot EC50 for Simian virus 40 A2895	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains.
AID303237	Cytotoxicity against HeLa cells assessed as alteration in morphology after 3 days	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID303209	Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID374193	Antiviral activity against Camelpox virus CML1 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID293234	Half life in rat liver in 37degC at 500 uM	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Synthesis and biological activation of an ethylene glycol-linked amino acid conjugate of cyclic cidofovir.
AID681331	TP_TRANSPORTER: inhibition of 6-Carboxyfluorescein uptake in OAT1-expressing CHO cells	2000	Analytical biochemistry, Jul-15, Volume: 283, Issue:1	Fluorescence-based assay for the interaction of small molecules with the human renal organic anion transporter 1.
AID606838	Drug uptake in fasted Albino Sprague-Dawley rat plasma at 10 mg/kg administered into gastrointestinal tract measured up to 4 hrs	2011	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13	Synthesis, transport and antiviral activity of Ala-Ser and Val-Ser prodrugs of cidofovir.
AID374222	Antiviral activity against Camelpox virus CML1-induced cytopathic effect in human PHK raft culture assessed as full protection of differentiated epithelium at 164uM treated after 7 days postinfection	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID324756	Antiviral activity against Murine polyomavirus PTA in mouse UC1B cells assessed as reduction of virus-induced cytopathogenicity	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains.
AID293236	Half life in Caco-2 cells in 37degC at 500 uM	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Synthesis and biological activation of an ethylene glycol-linked amino acid conjugate of cyclic cidofovir.
AID374206	Antiviral activity against Camelpox virus CML14 infected in HEL299 cells assessed as reduction in viral titer after 6 days postinfection by virus yield reduction assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID374208	Antiviral activity against Camelpox virus CML14 infected in human PHK assessed as reduction in viral titer after 6 days postinfection by virus yield reduction assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID293244	Bioavailability in rat at 3 mg, po	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Synthesis and biological activation of an ethylene glycol-linked amino acid conjugate of cyclic cidofovir.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	6 (28.57)	18.2507
2000's	10 (47.62)	29.6817
2010's	4 (19.05)	24.3611
2020's	1 (4.76)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (4.55%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	21 (95.45%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
adenine [no description available]	2.41	2	0	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
salicylic acid Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).	2	1	0	monohydroxybenzoic acid	algal metabolite; antifungal agent; antiinfective agent; EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor; keratolytic drug; plant hormone; plant metabolite
cytosine [no description available]	5.26	12	1	aminopyrimidine; pyrimidine nucleobase; pyrimidone	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
glutaric acid glutaric acid: RN given refers to parent cpd. glutaric acid : An alpha,omega-dicarboxylic acid that is a linear five-carbon dicarboxylic acid.	2	1	0	alpha,omega-dicarboxylic acid; dicarboxylic fatty acid	Daphnia magna metabolite; human metabolite
amantadine amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source	2.05	1	0	adamantanes; primary aliphatic amine	analgesic; antiparkinson drug; antiviral drug; dopaminergic agent; NMDA receptor antagonist; non-narcotic analgesic
p-aminohippuric acid p-Aminohippuric Acid: The glycine amide of 4-aminobenzoic acid. Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity.. p-aminohippurate : A hippurate that is the conjugate base of p-aminohippuric acid, arising from deprotonation of the carboxy group.. p-aminohippuric acid : An N-acylglycine that is the 4-amino derivative of hippuric acid; used as a diagnostic agent in the measurement of renal plasma flow.	2	1	0	N-acylglycine	Daphnia magna metabolite
foscarnet Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.. phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.	2.05	1	0	carboxylic acid; one-carbon compound; phosphonic acids	antiviral drug; geroprotector; HIV-1 reverse transcriptase inhibitor; sodium-dependent Pi-transporter inhibitor
ketoprofen Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.. ketoprofen : An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.	2	1	0	benzophenones; oxo monocarboxylic acid	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
nevirapine Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.	2.05	1	0	cyclopropanes; dipyridodiazepine	antiviral drug; HIV-1 reverse transcriptase inhibitor
olomoucine olomoucine: inhibits protein P34CDC2. olomoucine : A 9H-purine that is substituted by a (2-hydroxyethyl)nitrilo, benzylnitrilo and a methyl group at positions 2,6 and 9, respectively. It is a cyclin-dependent kinase inhibitor.	2.05	1	0	2,6-diaminopurines; ethanolamines	EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
probenecid Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.. probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.	2	1	0	benzoic acids; sulfonamide	uricosuric drug
delavirdine Delavirdine: A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.. delavirdine : The amide resulting from the formal condensation of 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylic acid and 4-amino group of 1-[3-(isopropylamino)pyridin-2-yl]piperazine, delavirdine is a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.	2.05	1	0	aminopyridine; indolecarboxamide; N-acylpiperazine; sulfonamide	antiviral drug; HIV-1 reverse transcriptase inhibitor
cephaloridine Cephaloridine: A cephalosporin antibiotic.. cefaloridine : A cephalosporin compound having pyridinium-1-ylmethyl and 2-thienylacetamido side-groups. A first-generation semisynthetic derivative of cephalosporin C.	2	1	0	beta-lactam antibiotic allergen; cephalosporin; semisynthetic derivative	antibacterial drug
idoxuridine [no description available]	2.05	1	0	organoiodine compound; pyrimidine 2'-deoxyribonucleoside	antiviral drug; DNA synthesis inhibitor
serine Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.	2.05	1	0	L-alpha-amino acid; proteinogenic amino acid; serine family amino acid; serine zwitterion; serine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
benzohydroxamic acid [no description available]	2.05	1	0
n-hydroxyphthalimide N-hydroxyphthalimide: causes contact dermititis	2.05	1	0
toyocamycin Toyocamycin: 4-Amino-5-cyano-7-(D-ribofuranosyl)-7H- pyrrolo(2,3-d)pyrimidine. Antibiotic antimetabolite isolated from Streptomyces toyocaensis cultures. It is an analog of adenosine, blocks RNA synthesis and ribosome function, and is used mainly as a tool in biochemistry.. toyocamycin : An N-glycosylpyrrolopyrimidine that is tubercidin in which the hydrogen at position 5 of the pyrrolopyrimidine moiety has been replaced by a cyano group.	2.05	1	0	antibiotic antifungal agent; N-glycosylpyrrolopyrimidine; nitrile; ribonucleoside	antimetabolite; antineoplastic agent; apoptosis inducer; bacterial metabolite
stavudine Stavudine: A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.. stavudine : A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase	2.05	1	0	dihydrofuran; nucleoside analogue; organic molecular entity	antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
5-azacytosine 5-azacytosine: structure given in first source. 5-azacytosine : A monoamino-1,3,5-triazine that is cytosine in which the aromatic CH at position 5 is replaced by a nitrogen.	2.08	1	0	monoamino-1,3,5-triazine
vidarabine adenine arabinoside : A purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond.	2.06	1	0	beta-D-arabinoside; purine nucleoside	antineoplastic agent; bacterial metabolite; nucleoside antibiotic
acetylpyruvic acid acetylpyruvic acid: structure. acetylpyruvic acid : A dioxo monocarboxylic acid that is pentanoic acid carrying two oxo groups at positions 2 and 4.	2.05	1	0	beta-diketone; dioxo monocarboxylic acid	bacterial metabolite
zalcitabine Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.. zalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.	2.05	1	0	pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
zidovudine Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.	2.05	1	0	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
ribavirin Rebetron: Rebetron is tradename	2.44	2	0	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
cephradine Cephradine: A semi-synthetic cephalosporin antibiotic.. cephradine : A first-generation cephalosporin antibiotic with a methyl substituent at position 3, and a (2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetamido substituent at position 7, of the cephem skeleton.	2	1	0	beta-lactam antibiotic allergen; cephalosporin	antibacterial drug
fialuridine [no description available]	2.05	1	0
adefovir adefovir: inhibitor of African swine fever virus. adefovir(1-) : A organophosphonate oxoanion obtained by removal of a proton from the phosphonate group of adefovir, a nucleoside reverse transcriptase inhibitor. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).. adefovir : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens has been replaced by a 2-(6-amino-9H-purin-9-yl)ethoxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(t-butoxycarbonyloxymethyl) ester (dipivoxil ester) prodrug is used to treat chronic hepatitis B viral infection.	2.94	4	0	6-aminopurines; ether; phosphonic acids	antiviral drug; DNA synthesis inhibitor; drug metabolite; HIV-1 reverse transcriptase inhibitor; nephrotoxic agent
cidofovir anhydrous Cidofovir: An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS.. cidofovir anhydrous : Cytosine substituted at the 1 position by a 3-hydroxy-2-(phosphonomethoxy)propyl group (S configuration). A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.	5.48	15	1	phosphonic acids; pyrimidone	anti-HIV agent; antineoplastic agent; antiviral drug; photosensitizing agent
lamivudine [no description available]	2.05	1	0	monothioacetal; nucleoside analogue; oxacycle; primary alcohol	allergen; anti-HBV agent; antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor; HIV-1 reverse transcriptase inhibitor; prodrug
zanamivir Zanamivir: A guanido-neuraminic acid that is used to inhibit NEURAMINIDASE.	2.05	1	0	guanidines	antiviral agent; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
adefovir dipivoxil bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine: structure given in first source. adefovir pivoxil : An organic phosphonate that is the dipivoxil ester of adefovir. A prodrug for adefovir, an HIV-1 reverse transcriptase inhibitor, adefovir pivoxil is used to treat chronic hepatitis B viral infection.	2.05	1	0	6-aminopurines; carbonate ester; ether; organic phosphonate	antiviral drug; DNA synthesis inhibitor; HIV-1 reverse transcriptase inhibitor; nephrotoxic agent; prodrug
efavirenz efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.	2.05	1	0	acetylenic compound; benzoxazine; cyclopropanes; organochlorine compound; organofluorine compound	antiviral drug; HIV-1 reverse transcriptase inhibitor
nelfinavir Nelfinavir: A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.. nelfinavir : An aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties.	2.05	1	0	aryl sulfide; benzamides; organic heterobicyclic compound; phenols; secondary alcohol; tertiary amino compound	antineoplastic agent; HIV protease inhibitor
9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine [no description available]	2.03	1	0
amprenavir [no description available]	2.05	1	0	carbamate ester; sulfonamide; tetrahydrofuryl ester	antiviral drug; HIV protease inhibitor
oseltamivir Oseltamivir: An acetamido cyclohexene that is a structural homolog of SIALIC ACID and inhibits NEURAMINIDASE.. oseltamivir : A cyclohexenecarboxylate ester that is the ethyl ester of oseltamivir acid. An antiviral prodrug (it is hydrolysed to the active free carboxylic acid in the liver), it is used to slow the spread of influenza.	2.05	1	0	acetamides; amino acid ester; cyclohexenecarboxylate ester; primary amino compound	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; environmental contaminant; prodrug; xenobiotic
2-Oxo-4-phenylbutyric acid [no description available]	2.05	1	0	benzenes
9-(s)-(3-hydroxy-2-(phosphonomethoxy)propyl)adenine [no description available]	2.96	4	0
9-(3-hydroxy-2-phosphonomethoxypropyl)-2,6-diaminopurine 9-(3-hydroxy-2-phosphonomethoxypropyl)-2,6-diaminopurine: RN refers to (S)-isomer	2.44	2	0
clevudine [no description available]	2.05	1	0
9-(2,3-dihydroxypropyl)adenine, (s)-isomer [no description available]	2.03	1	0
lopinavir [no description available]	2.05	1	0	amphetamines; dicarboxylic acid diamide	anticoronaviral agent; antiviral drug; HIV protease inhibitor
4-amino-5-bromo-7-(2-hydroxyethoxymethyl)pyrrolo(2,3-d)pyrimidine 4-amino-5-bromo-7-(2-hydroxyethoxymethyl)pyrrolo(2,3-d)pyrimidine: structure given in first source; 5-bromotubercidin in which the ribose is replaced by 2-hydroxyethoxymethyl	2.05	1	0
bcx 1812 [no description available]	2.05	1	0	3-hydroxy monocarboxylic acid; acetamides; cyclopentanols; guanidines	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
organophosphonates hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.	5	9	1	divalent inorganic anion; phosphite ion
cyclic-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine cyclic-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine: specific name and structure not given in first source	2.93	4	0
1-(benzenesulfonyl)indole [no description available]	2.05	1	0	sulfonamide
(north)-methanocarbathymidine (north)-methanocarbathymidine: also called NMCT. 1-[(1S,2S,4S,5R)-4-hydroxy-5-(hydroxymethyl)bicyclo[3.1.0]hexan-2-yl]thymine : A carbobicyclic compound that is bicyclo[3.1.0]hexane which is substituted at the 2-pro-S, 4-pro-S and 5-pro-R positions by thymin-1-yl, hydroxy, and hydroxymethyl groups, respectively.	2.05	1	0	C-glycosyl pyrimidine; carbobicyclic compound; primary alcohol; pyrimidone; secondary alcohol
mycophenolic acid Mycophenolic Acid: Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.. mycophenolate : A monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of mycophenolic acid.. mycophenolic acid : A member of the class of 2-benzofurans that is 2-benzofuran-1(3H)-one which is substituted at positions 4, 5, 6, and 7 by methyl, methoxy, (2E)-5-carboxy-3-methylpent-2-en-1-yl, and hydroxy groups, respectively. It is an antibiotic produced by Penicillium brevi-compactum, P. stoloniferum, P. echinulatum and related species. An immunosuppressant, it is widely used (partiularly as its sodium salt and as the 2-(morpholin-4-yl)ethyl ester prodrug, mycophenolate mofetil) to prevent tissue rejection following organ transplants and for the treatment of certain autoimmune diseases.	2.05	1	0	2-benzofurans; gamma-lactone; monocarboxylic acid; phenols	anticoronaviral agent; antimicrobial agent; antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; environmental contaminant; immunosuppressive agent; mycotoxin; Penicillium metabolite; xenobiotic
brivudine brivudine: anti-herpes agent	2.44	2	0
gs 4071 GS 4071: The acid form.. oseltamivir acid : A cyclohexenecarboxylic acid that is cyclohex-1-ene-1-carboxylic acid which is substituted at positions 3, 4, and 5 by pentan-3-yloxy, acetamido, and amino groups, respectively (the 3R,4R,5S enantiomer). An antiviral drug, it is used as the corresponding ethyl ester prodrug, oseltamivir, to slow the spread of influenza.	2.05	1	0	acetate ester; amino acid; cyclohexenecarboxylic acid; primary amino compound	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; marine xenobiotic metabolite
lamivudine triphosphate [no description available]	2.05	1	0
l 737126 5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: structure given in first source; an inhibitor of HIV-1 reverse transcriptase	2.05	1	0
ic9564 IC9564: betulinic acid derivative; structure in first source	2.05	1	0
tenofovir tenofovir (anhydrous) : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection.	2.05	1	0	nucleoside analogue; phosphonic acids	antiviral drug; drug metabolite; HIV-1 reverse transcriptase inhibitor
2,5,6-trichloro-1-(ribofuranosyl)benzimidazole [no description available]	2.05	1	0
gw 257406x maribavir: has antiviral activity against human cytomegalovirus	2.05	1	0
cmx 001 [no description available]	2.05	1	0
favipiravir favipiravir : A member of the class of pyrazines that is pyrazine substituted by aminocarbonyl, hydroxy and fluoro groups at positions 2, 3 and 6, respectively. It is an anti-viral agent that inhibits RNA-dependent RNA polymerase of several RNA viruses and is approved for the treatment of influenza in Japan.	2.05	1	0	hydroxypyrazine; organofluorine compound; primary carboxamide	anticoronaviral agent; antiviral drug; EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor
6-phosphonylmethoxyethoxy-2,4-diaminopyrimidine [no description available]	2.73	3	0
4-phenyl-4-oxo-2-hydroxybuten-2-oic acid 2,4-dioxo-4-phenylbutanoic acid: structure in first source	2.05	1	0
2-hydroxy-4h-isoquinoline-1,3-dione 2-hydroxy-4H-isoquinoline-1,3-dione: structure in first source	2.05	1	0
benzoylacrylic acid benzoylacrylic acid: structure in first source	2.05	1	0
at 61 AT 61: a phenylpropenamide derivative; structure in first source	2.05	1	0
2',3'-didehydro-3'-deoxy-4'-ethynylthymidine 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine: a highly active anti-HIV agent; structure in first source	2.05	1	0
vicriviroc vicriviroc: structure in first source	2.05	1	0	(trifluoromethyl)benzenes
hcv 371 [no description available]	2.05	1	0
2-acetylpyridine thiosemicarbazone 2-acetylpyridine thiosemicarbazone: RN given refers to parent cpd	2.06	1	0
bms 806 BMS 806: prevents entry of HIV into cells by binding HIV envelope protein gp120; no further info available 4/2002	2.05	1	0
flutimide flutimide: isolated from Delitschia confertaspora; selectively inhibits the transcriptase of influenza viruses; structure given	2.05	1	0
a 315675 [no description available]	2.05	1	0
rilpivirine [no description available]	2.05	1	0	aminopyrimidine; nitrile	EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor; HIV-1 reverse transcriptase inhibitor
bms 433771 [no description available]	2.05	1	0
acyclovir Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.	2.74	3	0	2-aminopurines; oxopurine	antimetabolite; antiviral drug
didanosine Didanosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.. didanosine : A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS.	2.05	1	0	purine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor; geroprotector; HIV-1 reverse transcriptase inhibitor
ganciclovir [no description available]	3.28	6	0	2-aminopurines; oxopurine	antiinfective agent; antiviral drug
penciclovir penciclovir : A member of the class of 2-aminopurines that is guanine in which the hydrogen at position 9 is substituted by a 4-hydroxy-3-(hydroxymethyl)but-1-yl group. An antiviral drug, it is administered topically for treatment of herpes labialis. A prodrug, famciclovir, is used for oral administration.	2.05	1	0	2-aminopurines; propane-1,3-diols	antiviral drug
cyclopropavir cyclopropavir: cyclopropavir is the (Z)-isomer; has antiviral activity; structure in first source	2.05	1	0
9-((2-phosphonylmethoxy)ethyl)guanine 9-((2-phosphonylmethoxy)ethyl)guanine: structure given in first source	2.03	1	0	phosphoethanolamine

Condition	Relationship Strength	Studies	Trials
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.72	3	0
Cytomegalovirus A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.	3.12	5	0
African Swine Fever A sometimes fatal ASFIVIRUS infection of pigs, characterized by fever, cough, diarrhea, hemorrhagic lymph nodes, and edema of the gallbladder. It is transmitted between domestic swine by direct contact, ingestion of infected meat, or fomites, or mechanically by biting flies or soft ticks (genus Ornithodoros).	2.41	1	0
B Virus Infection [description not available]	2.08	1	0
B-Cell Lymphoma [description not available]	2.08	1	0
Fibroma, Shope [description not available]	2.08	1	0
Lymphoma, B-Cell A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.	2.08	1	0
Disease, Pulmonary [description not available]	2.01	1	0
Vaccinia The cutaneous and occasional systemic reactions associated with vaccination using smallpox (variola) vaccine.	2.01	1	0
Cow Pox [description not available]	2.01	1	0
Lung Diseases Pathological processes involving any part of the LUNG.	2.01	1	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	2.01	1	0
Cytomegalic Inclusion Disease [description not available]	2.71	3	0
Cytomegalovirus Infections Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.	2.71	3	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	2.03	1	0
Cytomegaloviral Retinitis [description not available]	1.99	1	0
AIDS-Related Opportunistic Infections Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include PNEUMOCYSTIS PNEUMONIA, Kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with Mycobacterium avium complex, Microsporidium, and Cytomegalovirus.	1.99	1	0
Cytomegalovirus Retinitis Infection of the retina by cytomegalovirus characterized by retinal necrosis, hemorrhage, vessel sheathing, and retinal edema. Cytomegalovirus retinitis is a major opportunistic infection in AIDS patients and can cause blindness.	1.99	1	0
Viral Diseases [description not available]	1.99	1	0
Virus Diseases A general term for diseases caused by viruses.	1.99	1	0
HIV Coinfection [description not available]	3.38	1	1
HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).	3.38	1	1

cyclic-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine

Description

Cross-References

Synonyms (28)

Research Excerpts

Toxicity

Compound-Compound Interactions

Bioavailability

Dosage Studied

Protein Targets (1)

Inhibition Measurements

Other Measurements

Biological Processes (11)

Molecular Functions (11)

Ceullar Components (6)

Bioassays (91)

Research

Studies (21)

Market Indicators

Research Demand Index: 11.29

Study Types

cyclic-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine

Description

Cross-References

Synonyms (28)

Research Excerpts

Toxicity

Compound-Compound Interactions

Bioavailability

Dosage Studied

Protein Targets (1)

Inhibition Measurements

Other Measurements

Biological Processes (11)

Molecular Functions (11)

Ceullar Components (6)

Bioassays (91)

Research

Studies (21)

Market Indicators

Research Demand Index: 11.29

Study Types

Related Drugs (80)

Related Conditions (22)